

Combination therapy, including a macrolide antibiotic plus rifabutin, fluoroquinolones or ethambutol,^{5–8} for a minimum of 6 months is recommended to prevent resistance.

Surgical intervention, which in some studies is considered the treatment of choice,^{1,5,8,9} is not exempt from complications: superinfection of the surgical site and neurovascular lesions, such as facial nerve paralysis.^{3,7}

Drug therapy before or after surgery may help decrease the size of the excision site, thereby reducing the risk of bilateral brain injury, advanced lesions, fistulisation or recurrence.^{5,9}

Final comments

NTM-related infections of the parotid gland are rare and MT must be ruled out. Treatment must be personalised after assessing the risk-benefit ratio.

In our case, drug therapy prior to surgery considerably reduced the size of the lesion and minimised aesthetic sequelae.

Acknowledgements

We would like to thank everyone from the Paediatrics, ENT and Microbiology Departments at Hospital de Sant Pau.

References

1. Tortoli E. Epidemiology of cervico facial pediatric lymphadenitis as a result of nontuberculous mycobacteria. *Int J Mycobacteriol*. 2012;1:165–9.
2. Zimmermann P, Curtis N, Tebruegge M. Nontuberculous mycobacterial disease in childhood – update on diagnostic approaches and treatment. *J Infect*. 2017;74 Suppl. 1:S136–42.
3. Willemse SH, Oomens MAEM, de Lange J, Karssemakers LHE. Diagnosing nontuberculous mycobacterial cervicofacial lymphadenitis in children: a systematic review. *Int J Pediatr Otorhinolaryngol*. 2018;112:48–54.
4. Hermansen TS, Thomsen VØ, Lillebaek T, Ravn P. Non-tuberculous mycobacteria and the performance of interferon gamma release assays in Denmark. *PLOS ONE*. 2014;9:e93986.
5. Nuñez-Cuadros E, Baquero Artigao F, Grupo de trabajo sobre infección por micobacterias no tuberculosas de la Sociedad Española de Infectología Pediátrica (SEIP). Recomendaciones de la Sociedad Española de Infectología Pediátrica sobre el tratamiento de las adenitis por micobacterias no tuberculosas. *An Pediatr (Barc)*. 2012;77:147–222.
6. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing drug resistance mechanisms and therapy of infections with nontuberculous mycobacteria. *Clin Microbiol Rev*. 2012;25:545–82.
7. Tebruegge M, Pantazidou A, MacGregor D, Gonis G, Leslie D, Sedda L, et al. Nontuberculous mycobacterial disease in children – epidemiology, diagnosis & management at a tertiary center. *PLOS ONE*. 2016;11:e0147513.
8. Margje H, Arend SM, Lindeboom JA, Hartwig NG, van Dissel JT. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. *Clin Infect Dis*. 2004;39:450–6.
9. Spinelli G, Mannelli G, Arcuri F, Venturini E, Chiappini E, Galli L. Surgical treatment for chronic cervical lymphadenitis in children. Experience from a tertiary care paediatric center on non-tuberculous mycobacterial infections. *Int J Pediatr Otorhinolaryngol*. 2018;108:137–42.

Diana Carolina Juzga-Corrales^{a,*},
Elisenda Moliner-Calderón^a, Pere Coll-Figa^b, Xavier Leon-Vintró^c

^a Servicio de Pediatría, Hospital de Sant Pau, Barcelona, Spain

^b Servicio de Microbiología, Hospital de Sant Pau, Barcelona, Spain

^c Servicio de Otorrinolaringología, Hospital de Sant Pau, Barcelona, Spain

Corresponding author.

E-mail address: caroljcorrales@gmail.com (D.C. Juzga-Corrales).

<https://doi.org/10.1016/j.eimce.2019.04.012>

2529-993X/

© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Streptobacillus moniliformis bacteraemia: A case report



Bacteriemia por Streptobacillus moniliformis: a propósito de un caso

Dear Editor:

Streptobacillus moniliformis is a fastidious, pleomorphic, Gram-negative rod that is part of rodents' upper respiratory tract microbiota. *S. moniliformis* as well as *Spirillum minus* cause "rat-bite fever" (RBF) disease.¹

Here we report a case of bacteraemia and possible infectious endocarditis due to *S. moniliformis*. A 31-year-old man was admitted to the emergency department after a two-week history of fever and unspecific cutaneous lesions in some fingers and feet. He had little dotted lesions in both hands located only on the fingers but not on the palms. There were also other unspecific lesions on the sole of the feet. Blood samples were collected to perform further serologic studies. Considering that the patient general condition was good, he was discharged under paracetamol therapy and he was referred to the infectious diseases outpatient department. One week later, the patient returned to the hospital because of persistent fever as well as the appearance of arthralgia and additional skin lesions. After examining the patient, one and two millimetre-sized petechial and purpuric lesions were found on both hands (fingers and palms) and feet (the right toe and the left heel). Some of them were slightly bigger and similar to Osler's nodes. Neither cellulitis

nor oedema was observed. Empiric therapy was started with intravenous (IV) ceftriaxone 2 g/24 h due to infectious endocarditis suspicion.

The initial peripheral blood analysis (obtained one week before) and the new analysis results demonstrated normocytic anaemia, thrombocytosis, C-reactive protein value of 15 mg/L, erythrocyte sedimentation rate of 40 mm/h and normal values of rheumatoid factor, and serologic studies were negative (HIV, hepatitis, toxoplasma and *Treponema pallidum* serologies). Histopathological studies of skin lesions found small thrombi causing occlusive vasculopathy. Neither the ophthalmoscopic exam nor the transthoracic echocardiogram revealed any abnormalities.

Gram stain of the blood cultures (positive after 20 h incubation) showed thin and long Gram-negative bacilli. Microorganism identification directly from blood culture using MALDI-TOF mass spectrometry was not achieved. After a 72-h incubation under capnophilic atmosphere, small and greyish colonies grew on sheep blood agar subculture. Those colonies were identified using MALDI-TOF analysis as *S. moniliformis* with a 1.95 score. Identification by 16S rRNA PCR and sequencing yield a 709 bp amplified fragment that shared 99% identity with *S. moniliformis* ATCC49940 (acc. num. KP657489.1). Susceptibility testing was performed by the gradient diffusion (Etest) and disk-diffusion methods on sheep blood agar plates. The isolate was susceptible to penicillin (MIC: 0.03 mg/L), cefotaxime (MIC: 0.012 mg/L), imipenem (MIC: 0.012 mg/L), tetracycline (MIC: 0.38 mg/L) and ciprofloxacin (MIC 0.19 mg/L) and was resistant to aminoglycosides (MICs: tobramycin 8 mg/L, amikacin 32 mg/L and gentamycin 4 mg/L), colistin (MIC:

32 mg/L) and co-trimoxazole (MIC: >32 mg/L), in agreement with previous reports.^{1–3}

Since penicillin-resistance in *S. moniliformis* is extremely rare, the recommended treatment is penicillin.^{1,2,5} In our case, the empirical treatment with IV ceftriaxone 2 g/day was prolonged for four weeks due to its proved clinical efficacy against *S. moniliformis*, and the patient cured.^{4,5} Without proper treatment, the mortality associated to this disease is approximately 10%.^{1,3,4} In this case the patient could have presented a typical RBF onset (fever, polyarthralgias and polymorphic cutaneous lesions in both hands and feet^{1,3–5}); however, it was also difficult to distinguish between RBF and possible endocarditis.⁶ Indeed, positive results of 2 separate blood cultures with *S. moniliformis* (a microorganism with the ability to cause infective endocarditis) as major criteria, and the presence of fever, vascular (determined by histopathology) and immunological phenomena (Osler nodes-like) as minor criteria, posed concerns for the existence of possible infective endocarditis.

After knowing the blood culture results, the patient was asked about animal contact. He explained he had four dogs, two cats and two domestic rats, but he did not remember being bitten recently. Rats and other rodents are the main reservoir of *S. moniliformis* and its bite is directly related with RBF. Moreover, It can also be transmitted by contact with its saliva, excrements or through other colonized pets.^{1,3,4} No history of animal bites, which is the case of our patient, have also been reported by nearly 30% of the patients.^{2,5} Although, the incidence of RBF in Spain is unknown, several cases have been reported (three cases of bacteraemia and other cases of arthritis, abscesses and wound infection) after rodents' bite.² Overall, this case emphasizes the need for a high clinical suspicion and a well-addressed anamnesis, which was indeed performed inaccurately here, in order to diagnose this infectious disease.

S. moniliformis is a fastidious bacillus that requires microaerobic atmosphere (5–10% CO₂), long incubation period (2–7 days) and culture media with blood for its growth. In blood cultures it is inhibited by the presence of sodium polyanethol sulfonate (used as an anticoagulant in some blood cultures) but it is not affected by the presence of resins in the media.^{1–5} The incorporation of MALDI-TOF analysis in clinical Microbiology departments has reduced the time needed for optimal bacterial identification in such a fastidious microorganism.³ If there is a high clinical suspicion of RBF and difficulties in culturing samples, diagnosis carried out by 16S rRNA PCR analysis can be done.^{1,3,5}

In conclusion, infections caused by *S. moniliformis* in Spain are rare; ours is the fourth case of bacteraemia reported. History of

rodent contact and high clinical suspicion are essential in order to adapt laboratory protocols and to improve microbiological diagnosis and patient outcome.

Acknowledgements

We thank all the staff of the Microbiology and Infectious Diseases Departments who with their daily work contributed to the improvement of the patient's care.

References

1. Elliott SP. Rat bite fever and *Streptobacillus moniliformis*. Clin Microbiol Rev. 2007;20:13–22. <http://dx.doi.org/10.1128/CMR.00016-06>.
2. Barja JM, Castelo L, Almagro M, Sánchez-Vidal E, Fernández-González A, Peña-Rodríguez F, et al. Rat-bite fever: a case in Spain with skin lesions. Actas Dermosifiliogr. 2010;101:275–8. <http://dx.doi.org/10.1016/j.ad.2009.10.005>.
3. Kawakami Y, Katayama T, Kishida M, Oda W, Inoue Y. A case of *Streptobacillus moniliformis* infection with cutaneous leukocytoclastic vasculitis. Acta Med Okayama. 2016;70:377–81. <http://dx.doi.org/10.18926/AMO/54596>.
4. Hammer A, Wolff D, Geißdörfer W, Schrey M, Ziegler R, Steiner HH, et al. A spinal epidural abscess due to *Streptobacillus moniliformis* infection following a rat bite: case report. J Neurosurg Spine. 2017;27:92–6. <http://dx.doi.org/10.3171/2016.12.SPINE161042>.
5. Zamora-López MJ, Trigo Daporta M, García-Campello M, Millán Mon A, Mosquera Martínez JA. *Streptobacillus moniliformis*: in vivo and in vitro differences. Rev Esp Quimioter. 2017;30:382–4.
6. Habib G, Lancellotti P, Antunes MJ, Bongiorno MG, Casalta JP, Del Zotti F, et al. ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36:3075–128. <http://dx.doi.org/10.1093/eurheartj/ehv319>.

Dàmaris Berbel^{a,d}, Eva Romay^b, Oscar Murillo^c,
Carmen Ardanuy^{a,d,*}

^a Servicio de Microbiología, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain

^b Servicio de Medicina Interna, Hospital Universitario "Lucas Augusti", Lugo, Spain

^c Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain

^d CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain

* Corresponding author.

E-mail address: c.ardanuy@bellvitgehospital.cat (C. Ardanuy).

<https://doi.org/10.1016/j.eimc.2018.07.006>
0213-005X/

© 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Traveller's diarrhoea by *Vibrio cholerae* in patients returning from the Dominican Republic



Diarrea del viajero por *Vibrio cholerae* en pacientes que regresan de República Dominicana

Dear editor,

According to WHO and European Centre for Disease Control, only thirteen imported cases of cholera have been notified by Spain in the last 15 years, the last one in 2013. On August 20, 2015, *Vibrio cholerae* was isolated from two immunocompetent female patients (47 and 62 years-old) returning from Dominican Republic (DR). No patient had previously received the cholera vaccine. Both

patients showed acute and watery diarrhoea (12–15 stools/day, no blood and mucus), nausea, abdominal pain, and malaise. They had returned from a tourism trip to Bonao (DR) four days before, where they had stayed for 15 days. Physical examinations were normal, except for lightly dehydrated mucosae and skin. Laboratory analysis revealed hypokalemia and altered C-reactive protein. The patients informed the physician that a cholera outbreak had recently been detected in Bonao. This was related to drinking contaminated water from Masipetro river. They had not drunk contaminated water (only bottled water) or drinks with ice cubes, but they had swum in the Masipetro river during their stay. This information was notified as suspected cholera cases to the public health authorities. A blood and faecal culture from each patient were sent to the microbiology department. Intravenous fluids, metoclopramide and antibiotic treatment (Doxycycline 100 mg for 3 days) were started.